Vimarsana
Biggest News Aggregation in the World

Page 9 - Translational Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Translational Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Translational Sciences Today - Breaking & Trending Today

NIH clinical trial conducted in part at Arkansas Children's produces first FDA-approved treatment for multiple severe food allergies | Regional News - Vimarsana News

NIH clinical trial conducted in part at Arkansas Children's produces first FDA-approved treatment for multiple severe food allergies | Regional News

A groundbreaking clinical trial sponsored and funded by the National Institutes of Health (NIH) and conducted in part at Arkansas Children's Hospital (ACH) unveiled a pioneering treatment helping children and

New medicines – minus animal testing – is Pitt research goal - Vimarsana News

New medicines – minus animal testing – is Pitt research goal

(TNS) — Developing new drugs has involved animal testing since Aristotle, but the University of Pittsburgh is taking a lead in changing all that.

Every Cure to Receive $48.3M from ARPA-H to Develop AI-Driven Platform to Revolutionize Future of Drug Development and Repurposing - Vimarsana News

Every Cure to Receive $48.3M from ARPA-H to Develop AI-Driven Platform to Revolutionize Future of Drug Development and Repurposing

Every Cure, a nonprofit on a mission to save lives by repurposing existing medicines, announced today...

FDA Using AI in Drug Surveillance; Health Systems Move Ahead With AI; RAISE Guidance - Vimarsana News

FDA Using AI in Drug Surveillance; Health Systems Move Ahead With AI; RAISE Guidance

A monthly roundup of healthcare-focused AI news and research

Debate on cell and gene therapy longevity and compliance - Vimarsana News

Debate on cell and gene therapy longevity and compliance

SelectScience is hosting a new Accelerating Science Forum event on February 27, 2024, and invites you to attend.